CANDEL THERAPEUTICS INC. - COMMON STOCK

Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer

17 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights

30 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day

01 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference

12 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer

06 Dec 2022 15:26:35 By Nasdaq GlobeNewswire

Candel Therapeutics to Host Virtual R&D Day on December 6, 2022

29 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting

18 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma

11 Nov 2022 11:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

10 Nov 2022 07:00:03 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO

07 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Candel Therapeutics Upcoming Investor Conference Participation for November

01 Nov 2022 07:00:03 By Nasdaq GlobeNewswire

Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models

26 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for CAN-2409 in Glioma

15 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Two Executive Leadership Appointments

07 Sep 2022 07:00:02 By Nasdaq GlobeNewswire

Candel Therapeutics Upcoming Investor Conference Participation

06 Sep 2022 07:00:02 By Nasdaq GlobeNewswire

Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

05 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer

26 May 2022 16:30:00 By Nasdaq GlobeNewswire

Candel Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

18 May 2022 07:00:01 By Nasdaq GlobeNewswire

Candel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

12 May 2022 07:00:02 By Nasdaq GlobeNewswire

Candel Therapeutics to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

27 Apr 2022 15:00:00 By Nasdaq GlobeNewswire